Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 22, 2021
- Accepted in final form January 14, 2022
- First Published March 1, 2022.
Author Disclosures
- Anne Louise Oaklander, MD, PhD,
- Alexander J. Mills, BS (amills8{at}mgh.harvard.edu),
- Mary Kelley, DO (mary.kelley{at}ascension.org),
- Lisa S. Toran, MD (ltoranca{at}gmail.com),
- Bryan Smith, MD (bryan.smith2{at}nih.gov),
- Marinos C. Dalakas, MD (marinos.dalakas{at}jefferson.edu)* and
- Avindra Nath, MD (natha{at}ninds.nih.gov)*
- Anne Louise Oaklander, MD, PhD,
Non-profit entity Scientific Advisory Board: Pain Research Forum
NONE
NONE
Neurology® Neuroimmunology & Neuroinflammation, Associate Editor 2020-
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
2020Â2025 NIH 2 R01 NS093653-06 Evaluation of small-fiber polyneuropathy in youth. Principal Investigator
NONE
The Mayday Fund 2019-2021 NextGen|HSN-Precision medicine for early stage genetic small-fiber polyneuropathy. Principal Investigator Stock/Stock Options, Medical Equipment & Materials: Biogen, 2020
NONE
NONE
NONE
NONE
NONE
NONE
- Alexander J. Mills, BS (amills8{at}mgh.harvard.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mary Kelley, DO (mary.kelley{at}ascension.org),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lisa S. Toran, MD (ltoranca{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
Confluence Health, Neurologist, 3.5 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bryan Smith, MD (bryan.smith2{at}nih.gov),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marinos C. Dalakas, MD (marinos.dalakas{at}jefferson.edu)* and
Serves on the CIDP DSMB for Octapharma
NONE
OCTAPHARMA, TAKEDA, Alexion, Argenx, Grifols
1. Neurology, editorial board (several years, not compensated; rotated-off a year ago); 2) Acta Myologica, editorial board (several years, not compensated); 3)Acta Neurologica Scandinavica, editorial board ( several years, not compensated); 4)Therapeutic Advances in Neurology (Associate Editor; 5 years, compensated); 5) Annals of Neurology (3 years, not compensated-rotated-off a year ago); 6) Neurology, Neuroimmunology Neuroinflammation (Associate Editor, compensated); 7)Neurodiem (Associate editor, compensated); 8) Clinical Practice Elsevier (commentator-compensated) 9) Neurotherapeutics, editorial board (non-compensated)
NONE
NONE
NONE
Grifols, Octapharma, Dysimmune Diseases Foundation
NONE
NONE
NONE
Received Institutional support to Thomas Jefferson University Neurology department or to Neuroimmunology Unit, University of Athens Medical School for research and education from: Merck-Serono, Novartis, Guillain-Barre/CIDP Foundation, Dysimmune diseases Foundation, InfuCare, and Newfactor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Avindra Nath, MD (natha{at}ninds.nih.gov)*
NONE
NONE
NONE
Associate Editor, Journal of Neurovirology Editor, Practice Neurology Section Editor, Frontiers in Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH intramural funds
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Nerve Unit (A.L.O., A.J.M.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston; Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Boston, Massachusetts; Department of Neurology (M.K.), Dell Medical School, The University of Texas, Austin, Texas; Department of Neurology (L.S.T.), Confluence Health, Wenatchee; Section of Infections of the Nervous System (B.S., A.N.), National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), Bethesda, Maryland; and Neuromuscular Division (M.C.D.), Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, and National and Kapodistrian University of Athens Medical School, Greece.
- Correspondence
Dr. Oaklander aloaklander{at}mgh.harvard.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Podcast
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.